drugset / Trial / NCT04309643

Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects

NCT04309643

Phase 1 Completed 21 enrolled Concert Pharmaceuticals Celerion · collab
SequentialOpen-labelOther

Summary

This is a Phase 1, fixed sequence, multiple dose, open-label study of the effect of CTP-543 on oral contraceptive pharmacokinetics in healthy female subjects.

Timeline

Start
2020-06-09
Primary completion
2020-06-25
Completion
2020-07-08

Drugs

EvaluationDrugModalityDoseRoute
Subject CTP-543 Unknown Oral
Subject Levonorgestrel Small molecule 0.15 mg Oral
Subject ethinyl estradiol Small molecule 0.03 mg Oral

Indications

No indication recorded.